China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Google Halts UK YouTube TV Measurement Service After Legal Action 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
The Maire - EuroChem Case: Three Lessons for Global Business 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
BRISBANE, Calif., May 19, 2017 -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release preliminary financial results for the first quarter 2017 after the market closes on Monday, May 22, 2017. Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will host a conference call to review the Company’s results beginning at 1:30pm PT/4:30pm ET.
Individuals interested in listening to the conference call may do so by dialing (855) 420-0616 for domestic callers or (678) 304-6848 for international callers. Please reference Conference ID: 18923938. To listen to a live webcast, please visit the investor relations section of CareDx's website at: www.CareDx.com.
A replay of the call will be available beginning May 22, 2017 at 4:30 pm PT/7:30 pm ET through 4:30 pm PT/7:30 pm ET on May 23, 2017. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 18923938. The webcast will also be available on CareDx's website for one year following the completion of the call.
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®,and Olerup SBT Resolver™ for pre-transplant HLA testing.
For more information, please visit: www.CareDx.com.
Investor Contact Caroline Corner, Managing Director Westwicke Partners, LLC T: +1 415-202-5678 E: [email protected]
